PH12015500915A1 - Bremelanotide therapy for female sexual dysfunction - Google Patents

Bremelanotide therapy for female sexual dysfunction

Info

Publication number
PH12015500915A1
PH12015500915A1 PH12015500915A PH12015500915A PH12015500915A1 PH 12015500915 A1 PH12015500915 A1 PH 12015500915A1 PH 12015500915 A PH12015500915 A PH 12015500915A PH 12015500915 A PH12015500915 A PH 12015500915A PH 12015500915 A1 PH12015500915 A1 PH 12015500915A1
Authority
PH
Philippines
Prior art keywords
bremelanotide
sexual dysfunction
female sexual
therapy
women
Prior art date
Application number
PH12015500915A
Other languages
English (en)
Other versions
PH12015500915B1 (en
Inventor
Spana Carl
Jordan Robert
Jeffrey D Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015500915(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of PH12015500915B1 publication Critical patent/PH12015500915B1/en
Publication of PH12015500915A1 publication Critical patent/PH12015500915A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
PH12015500915A 2012-11-05 2015-04-23 Bremelanotide therapy for female sexual dysfunction PH12015500915A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
PH12015500915B1 PH12015500915B1 (en) 2015-06-29
PH12015500915A1 true PH12015500915A1 (en) 2015-06-29

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015500915A PH12015500915A1 (en) 2012-11-05 2015-04-23 Bremelanotide therapy for female sexual dysfunction

Country Status (23)

Country Link
US (7) US9352013B2 (https=)
EP (1) EP2916856B2 (https=)
JP (1) JP6567971B2 (https=)
KR (1) KR102253526B1 (https=)
CN (2) CN104755094A (https=)
AU (1) AU2013337341B2 (https=)
BR (1) BR112015009936A8 (https=)
DK (1) DK2916856T4 (https=)
EA (1) EA032959B9 (https=)
ES (1) ES2701444T5 (https=)
FI (1) FI2916856T4 (https=)
GE (2) GEAP201813826A (https=)
HK (1) HK1211227A1 (https=)
IL (1) IL238276B (https=)
MX (1) MX362610B (https=)
MY (1) MY179755A (https=)
NZ (1) NZ707246A (https=)
PH (1) PH12015500915A1 (https=)
PL (1) PL2916856T5 (https=)
SG (1) SG11201502949QA (https=)
UA (1) UA118656C2 (https=)
WO (1) WO2014071339A2 (https=)
ZA (1) ZA201503128B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1289587B1 (en) * 2000-05-31 2005-08-03 Novo Nordisk A/S A disposable double pointed injection needle
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
BRPI0518978A2 (pt) * 2004-12-09 2008-12-16 West Pharm Serv Inc seringa de injeÇço e retraÇço automÁtica
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
KR101687037B1 (ko) * 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
JP5809242B2 (ja) * 2010-04-21 2015-11-10 アッヴィ バイオテクノロジー リミテッド 治療薬の制御送達のための装着型自動注入装置

Also Published As

Publication number Publication date
SG11201502949QA (en) 2015-06-29
PL2916856T5 (pl) 2024-01-29
FI2916856T4 (fi) 2024-01-15
WO2014071339A2 (en) 2014-05-08
MX362610B (es) 2019-01-28
DK2916856T4 (da) 2024-01-22
KR102253526B1 (ko) 2021-05-18
HK1211227A1 (en) 2016-05-20
EP2916856A2 (en) 2015-09-16
NZ707246A (en) 2019-03-29
JP2016503406A (ja) 2016-02-04
US20140378392A1 (en) 2014-12-25
MY179755A (en) 2020-11-12
IL238276B (en) 2020-04-30
PH12015500915B1 (en) 2015-06-29
US20190216888A1 (en) 2019-07-18
US9352013B2 (en) 2016-05-31
US10286034B2 (en) 2019-05-14
US20210060120A1 (en) 2021-03-04
UA118656C2 (uk) 2019-02-25
JP6567971B2 (ja) 2019-08-28
AU2013337341A1 (en) 2015-05-07
DK2916856T3 (en) 2019-01-14
ES2701444T3 (es) 2019-02-22
EP2916856B1 (en) 2018-09-19
EP2916856B2 (en) 2023-10-18
US20150231196A1 (en) 2015-08-20
CN117860866A (zh) 2024-04-12
EP2916856A4 (en) 2016-06-22
GEP20196947B (en) 2019-02-11
EA032959B1 (ru) 2019-08-30
US20240335502A1 (en) 2024-10-10
US20220362328A1 (en) 2022-11-17
WO2014071339A3 (en) 2014-06-12
ZA201503128B (en) 2016-11-30
CA2890081A1 (en) 2014-05-08
IL238276A0 (en) 2015-06-30
CN104755094A (zh) 2015-07-01
AU2013337341B2 (en) 2018-02-22
KR20150081345A (ko) 2015-07-13
ES2701444T5 (es) 2024-05-21
GEAP201813826A (en) 2018-10-25
EA032959B9 (ru) 2019-11-27
BR112015009936A8 (pt) 2019-09-17
EA201590760A1 (ru) 2015-10-30
MX2015005486A (es) 2015-11-13
BR112015009936A2 (pt) 2017-07-11
US9700592B2 (en) 2017-07-11
PL2916856T3 (pl) 2019-02-28
US20180085425A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ714963A (en) Compositions and methods for treating anemia
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
ZA201806684B (en) Methods of treating pediatric cancers
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
UA117581C2 (uk) Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат
MY204827A (en) Semaglutide in medical therapy
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
UA115250C2 (uk) Фармацевтичні комбінації
PH12021552977A1 (en) Methods of treating urinary system cancers
PH12015500915A1 (en) Bremelanotide therapy for female sexual dysfunction
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NZ599227A (en) Therapeutic agent for chronic pain
ZA202100604B (en) Methods to reduce complications of intra-articular steroid
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
ZA202102913B (en) Dosage regime